Detalles de la búsqueda
1.
Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
Br J Cancer
; 130(5): 769-776, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38184691
2.
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Lancet Oncol
; 24(3): 297-306, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36739879
3.
Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.
Br J Cancer
; 126(3): 440-448, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34811505
4.
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
Oncologist
; 27(7): e571-e579, 2022 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35289915
5.
Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.
BMC Cancer
; 22(1): 742, 2022 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35799138
6.
Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer.
BMC Med Res Methodol
; 21(1): 14, 2021 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33422006
7.
Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
Acta Oncol
; 60(9): 1114-1121, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34197269
8.
Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study.
Gut
; 69(4): 681-690, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31780575
9.
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Gut
; 69(3): 531-539, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31101691
10.
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
Br J Cancer
; 122(7): 957-962, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32015513
11.
The area between ROC curves, a non-parametric method to evaluate a biomarker for patient treatment selection.
Biom J
; 62(6): 1476-1493, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32346912
12.
Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study.
Br J Cancer
; 119(4): 424-428, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29872148
13.
Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial.
BMC Cancer
; 15: 511, 2015 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26156156
14.
Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307).
Health Qual Life Outcomes
; 13: 151, 2015 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26391356
15.
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
Cancers (Basel)
; 16(8)2024 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38672597
16.
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
JAMA Oncol
; 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38573643
17.
Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002.
BMC Cancer
; 13: 281, 2013 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23758655
18.
Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial.
Dig Liver Dis
; 55(6): 791-798, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36725401
19.
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.
Exp Hematol Oncol
; 12(1): 63, 2023 Jul 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37480095
20.
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
JAMA Oncol
; 9(10): 1356-1363, 2023 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37535388